Skip to content
value.today

Cingulate Inc.: financial analysis

Ratios worked out from 7 fiscal years of Cingulate Inc.'s statements, compared with 665 companies in Biotechnology.

Return on equity, 2025
-450.4%
Biotechnology: -61.0%

Cingulate Inc. scorecard#

Passes 1 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median33.0×Price to book 33.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-21.0%Free cash flow is -21.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.44 vs -10.86Diluted EPS -4.44 in fiscal 2025 against -10.86 the year before (report's currency).
    • ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$7 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-450.4%-450.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.16 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-22.2×Operating income -22.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year231.5%Diluted shares up 231.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Net loss of $22 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$17 million.
  • The share count rose 231.5% in the year.
  • Operating income covers the interest bill only -22.2 times.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

1of 6(3 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

Cingulate Inc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Return on equity-450.4%——-143.0%-187.2%-61.0%3%
Return on assets-150.0%-180.5%-315.8%-103.1%-144.4%-44.4%12%

Financial strength#

Cingulate Inc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Interest cover-22.16×-521.33×-28.81×-60.34×-689.33×-22.77×51%
Current ratio1.16×2.55×0.06×1.12×16.00×4.39×15%
Equity share of assets16.7%50.2%-196.9%34.0%91.0%64.7%22%

Cash#

Cingulate Inc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$-17 M$-19 M$-15 M$-16 M$-11 M$-40 M66%

Shareholder returns#

Cingulate Inc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Change in share count231.5%—-87.5%——17.3%6%

How each figure is worked out#

Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Change in share count
Diluted shares against the year before. Negative: fewer shares.

Source: Cingulate Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Cingulate Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Cingulate Inc.